TALIS HEALTHCARE
AN INFUSION MANAGEMENT COMPANY

AVSOLA®

Please Fax Completed Form To: **888-898-9113**

PATIENT INFORMATION (Complete or Fax Existing Chart)

Name: ____________________________ DOB: ____________
Address: ____
City, State, Zip: _________________________________
Phone: _________________ Alt. Phone: ________________
Email: _______________________ SS#: _________________
Gender: ☐ M ☐ F Weight: _______(lbs) Ht: ______________
Allergies: _______________________________________

PRESCRIBER INFORMATION

Prescriber Name: ___________________________________
State License: _____________________________________
NPI #: _______________ DEA: _______________________
Address: ____
City, State, Zip: ____________________________________
Phone: ____________________ Fax: ___________________
Office Contact: ____________________ Phone: _____________

INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)

Primary Insurance: __________________________________
City, State, Zip: ____________________________________
Plan #: ____
Group #: ____
Phone: ____

RX Card (PBM): ____________________________________
BIN: ______________________ PCN: ___________________
City, State, Zip: ____________________________________
Group #: ____
Phone: ____

CLINICAL INFORMATION

☐ K51.90 Moderate to Severe Ulcerative Colitis
☐ K50.90 Moderate to Severe Crohn's Disease
☐ M06.9 Rheumatoid Arthritis
☐ M45.9 Ankylosing Spondylitis
☐ L40.52 Psoriatic Arthritis
☐ L40.0 Plaque Psoriasis
☐ Other: ___________________________

*If PPD test results are not within 12 months, please perform PPD.
Tuberculosis Screening: ☐ PPD Test Date: _____-_____-_____
Results: ☐ Negative
☐ Positive → ☐ Chest X-Ray Performed Date: ____-_____-_____
X-Ray Results: ☐ Negative
☐ Positive → TB treatment Initiated

Labs:
☐ CBC q: ________ ☐ CMP q: ________ ☐ CRP q: ________ ☐ ESR q:________ ☐ LFTs q: ________ ☐ X-Ray: ________ ☐ Other: _________

AVSOLA® ORDERS

Prescription type: ☐ New start ☐ Restart ☐ Continued therapy Total Doses Received: ___________ Date of Last Infusion: _____________

Medication	Directions	Quantity/Refills
Avsola® (infliximab-axxq)	**Loading dose:** ☐ 5mg/kg __________ mg IV at week: 0, 2, 6 ☐ 3mg/kg ______________________ mg IV at week: 0, 2, 6 ☐ Other: ____ ☐ **Maintenance dose:** (________ mg/kg) _______ mg IV every ______ weeks	**Loading dose:** 3 doses. No refills. **Maintenance dose:** 8-week supply. Refill x 1 year unless noted otherwise. ☐ ________________ week supply Refill x 1 year unless noted otherwise. ☐ Other: ___________________________

PRE-MEDICATIONS

☐ Diphenhydramine _______mg, ☐ PO -or- ☐ IV, prior to start of infusion
☐ Acetaminophen 650 mg PO prior to start of infusion
☐ Prednisone _____mg, PO -or- ☐ Methylprednisolone 40 mg IVP -or- ☐ Hydrocortisone 100 mg IVP
☐ Other: ____

ANAPHYLACTIC REACTION (AR):

☐ EpiPen® Auto-injector 0.3 mg (1:1000) Inject IM -or- SubQ to patients who weigh ≥ 66 lbs (≥ 30 kg); may repeat in 3-5 mins x 1 if necessary
☐ EpiPen Jr® Auto-injector 0.15mg (1:2000) Inject IM -or- SubQ to patients who weigh 33 - 66 lbs (15-30 kg): may repeat in 3-5 mins x 1 if necessary
☐ Diphenhydramine 50mg (1mL) - Give 50 mg slow IVP, administer IM if no IV access; may repeat x 1 after 10 mins, if necessary
☐ Hydrocortisone 100mg - Give 100 mg IVP -or- IM if no IV access
☐ Sodium Chloride 0.9% 500 mL infuse IV at a rate of 30 mL/hr
☐ Other: ____

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

TALIS HEALTHCARE
AN INFUSION MANAGEMENT COMPANY

AVSOLA®

Please Fax Completed Form To: **888-898-9113**

IV ACCESS

☐ Start PIV if no IV access available ☐ Maintain current central line access

MONITORING PARAMETERS

☐ Obtain vital signs and temperature every 15 mins for the 1st hour, then every 30 mins for the remainder of the infusion

☐ Observe patient for 30 mins following the infusion

☐ Instruct patient to report symptoms of chills, fever, headache, sore throat, pain, etc.

☐ Other: ____

CATHETER CARE

☐ Sodium Chloride 0.9% _____ mL IV before and after each IV access and PRN per protocol

☐ Sodium Chloride 0.9% _____ mL as above AND Heparin 100 Units /mL _____ mL IV flush after second saline flush and PRN

☐ Dressing changes weekly and PRN ☐ Antimicrobial dressing PRN

☐ May obtain blood from IV access for labs ☐ May use Cathflo 2 mg/2 mL sterile water IVP 2 mL per lumen; May repeat after 2 hours x 1

STANDARD ORDER FOR SIDE EFFECTS

☐ Promethazine 25 mg – 1-2 tabs po q 4-6 hrs PRN nausea / vomiting ☐ Diphenhydramine 25 mg - 1 to 2 caps po PRN

☐ Acetaminophen 325 mg - 2 tabs po q 4-6 hrs PRN HA, myalgia, fever ☐ Diphenhydramine 25 mg -or- 50 mg IV x 1 dose PRN

☐ Promethazine 25 mg IV/IM x 1 dose PRN nausea / vomiting ☐ Other: ____

SIGNATURE

We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral

X____ Date: ____________________

Prescriber Signature

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.